 |
|
|
REFERENCES
451.
Stanski DR, Ham J, Miller RD, et al: Time-dependent
increase in sensitivity to d-tubocurarine during
enflurane anesthesia in man. Anesthesiology 52:483–487, 1980.
452.
Withington DE, Donati F, Bevan DR, et al: Potentiation
of atracurium neuromuscular blockade by enflurane: Time-course of effect. Anesth
Analg 72:469–473, 1991.
453.
Rupp SM, Miller RD, Gencarelli PJ: Vecuronium-induced
neuromuscular blockade during enflurane, isoflurane, and halothane anesthesia in
humans. Anesthesiology 60:102–105, 1984.
454.
Gencarelli PJ, Miller RD, Eger EI 2nd, et al:
Decreasing enflurane concentrations and d-tubocurarine
neuromuscular blockade. Anesthesiology 56:192–194, 1982.
455.
Miller RD, Way WL, Dolan WM, et al: Comparative
neuromuscular effects of pancuronium, gallamine, and succinylcholine during forane
and halothane anesthesia in man. Anesthesiology 35:509–514, 1971.
456.
Wright PM, Hart P, Lau M, et al: The magnitude
and time course of vecuronium potentiation by desflurane versus isoflurane. Anesthesiology
82:404–411, 1995.
457.
Wulf H, Ledowski T, Linstedt U, et al: Neuromuscular
blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anaesthesia.
Can J Anaesth 45:526–532, 1998.
458.
Bock M, Klippel K, Nitsche B, et al: Rocuronium
potency and recovery characteristics during steady-state desflurane, sevoflurane,
isoflurane or propofol anaesthesia. Br J Anaesth 84:43–47, 2000.
459.
Paul M, Fokt RM, Kindler CH, et al: Characterization
of the interactions between volatile anesthetics and neuromuscular blockers at the
muscle nicotinic acetylcholine receptor. Anesth Analg 95:362–367, 2002.
460.
Yasuda N, Lockhart SH, Eger EI 2nd, et al: Comparison
of kinetics of sevoflurane and isoflurane in humans. Anesth Analg 72:316–324,
1991.
461.
Yasuda N, Lockhart SH, Eger EI 2nd, et al: Kinetics
of desflurane, isoflurane, and halothane in humans. Anesthesiology 74:489–498,
1991.
462.
Pereon Y, Bernard JM, Nguyen The Tich S, et al:
The effects of desflurane on the nervous system: From spinal cord to muscles.
Anesth Analg 89:490–495, 1999.
463.
Brett RS, Dilger JP, Yland KF: Isoflurane causes
"flickering" of the acetylcholine receptor channel: Observations using the patch
clamp. Anesthesiology 69:161–170, 1988.
464.
Franks NP, Lieb WR: Molecular and cellular mechanisms
of general anaesthesia. Nature 367:607–614, 1994.
465.
Dilger JP, Vidal AM, Mody HI, et al: Evidence
for direct actions of general anesthetics on an ion channel protein. A new look
at a unified mechanism of action. Anesthesiology 81:431–442, 1994.
466.
al Ahdal O, Bevan DR: Clindamycin-induced neuromuscular
blockade. Can J Anaesth 42:614–617, 1995.
467.
Sanders WE Jr, Sanders CC: Toxicity of antibacterial
agents: Mechanism of action on mammalian cells. Annu Rev Pharmacol Toxicol 19:53–83,
1979.
468.
Singh YN, Harvey AL, Marshall IG: Antibiotic-induced
paralysis of the mouse phrenic nerve-hemidiaphragm preparation, and reversibility
by calcium and by neostigmine. Anesthesiology 48:418–424, 1978.
469.
Wright JM, Collier B: Characterization of the
neuromuscular block produced by clindamycin and lincomycin. Can J Physiol Pharmacol
54:937–944, 1976.
470.
Lee C, de Silva AJ: Interaction of neuromuscular
blocking effects of neomycin and polymyxin B. Anesthesiology 50:218–220, 1979.
471.
Singh YN, Marshall IG, Harvey AL: Depression
of transmitter release and postjunctional sensitivity during neuromuscular block
produced by antibiotics. Br J Anaesth 51:1027–1033, 1979.
472.
Sokoll MD, Gergis SD: Antibiotics and neuromuscular
function. Anesthesiology 55:148–159, 1981.
473.
Becker LD, Miller RD: Clindamycin enhances a
nondepolarizing neuromuscular blockade. Anesthesiology 45:84–87, 1976.
474.
Burkett L, Bikhazi GB, Thomas KC Jr, et al: Mutual
potentiation of the neuromuscular effects of antibiotics and relaxants. Anesth Analg
58:107–115, 1979.
475.
Hasfurther DL, Bailey PL: Failure of neuromuscular
blockade reversal after rocuronium in a patient who received oral neomycin. Can
J Anaesth 43:617–620, 1996.
476.
Martinez EA, Mealey KL, Wooldridge AA, et al:
Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced
neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized
dogs. Am J Vet Res 57:1623–1626, 1996.
477.
Heier T, Caldwell JE, Sessler DI, et al: Mild
intraoperative hypothermia increases duration of action and spontaneous recovery
of vecuronium blockade during nitrous oxide-isoflurane anesthesia in humans. Anesthesiology
74:815–819, 1991.
478.
Leslie K, Sessler DI, Bjorksten AR, et al: Mild
hypothermia alters propofol pharmacokinetics and increases the duration of action
of atracurium. Anesth Analg 80:1007–1014, 1995.
479.
Caldwell JE, Heier T, Wright PM, et al: Temperature-dependent
pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology 92:84–93,
2000.
480.
Heier T, Caldwell JE, Sessler DI, et al: The
relationship between adductor pollicis twitch tension and core, skin, and muscle
temperature during nitrous oxide-isoflurane anesthesia in humans. Anesthesiology
71:381–384, 1989.
481.
Heier T, Caldwell JE, Sessler DI, et al: The
effect of local surface and central cooling on adductor pollicis twitch tension during
nitrous oxide/isoflurane and nitrous oxide/fentanyl anesthesia in humans. Anesthesiology
72:807–811, 1990.
482.
Ham J, Miller RD, Benet LZ, et al: Pharmacokinetics
and pharmacodynamics of d-tubocurarine during hypothermia
in the cat. Anesthesiology 49:324–329, 1978.
483.
Miller RD, Agoston S, van der Pol F, et al: Hypothermia
and the pharmacokinetics and pharmacodynamics of pancuronium in the cat. J Pharmacol
Exp Ther 207:532–538, 1978.
484.
Hubbard JI, Jones SF, Landau EM: The effect of
temperature change upon transmitter release, facilitation and post-tetanic potentiation.
J Physiol 216:591–609, 1971.
485.
Beaufort TM, Proost JH, Maring J, et al: Effect
of hypothermia on the hepatic uptake and biliary excretion of vecuronium in the isolated
perfused rat liver. Anesthesiology 94:270–279, 2001.
486.
Beaufort AM, Wierda JM, Belopavlovic M, et al:
The influence of hypothermia (surface cooling) on the time-course of action and
on the pharmacokinetics of rocuronium in humans. Eur J Anaesthesiol Suppl 11:95–106,
1995.
487.
Stenlake JB, Hughes R: In vitro degradation of
atracurium in human plasma. Br J Anaesth 59:806–807, 1987.
488.
De Jong RH, Hershey WN, Wagman IH: Nerve conduction
velocity during hypothermia in man. Anesthesiology 27:805–810, 1966.
489.
Eriksson LI, Viby-Mogensen J, Lennmarken C: The
effect of peripheral hypothermia on a vecuronium-induced neuromuscular block. Acta
Anaesthesiol Scand 35:387–392, 1991.
490.
Thornberry EA, Mazumdar B: The effect of changes
in arm temperature on neuromuscular monitoring in the presence of atracurium blockade.
Anaesthesia 43:447–449, 1988.
491.
Young ML, Hanson CW 3rd, Bloom MJ, et al: Localized
hypothermia influences assessment of recovery from vecuronium neuromuscular blockade.
Can J Anaesth 41:1172–1177, 1994.
492.
Miller RD, Van Nyhis LS, Eger EI: The effect
of temperature on a d-tubocurarine neuromuscular
blockade and its antagonism by neostigmine. J Pharmacol Exp Ther 195:237–241,
1975.
493.
Miller RD, Roderick LL: Pancuronium-induced neuromuscular
blockade, and its antagonism by neostigmine, at 29, 37, and 41 c. Anesthesiology
46:333–335, 1977.
494.
Heier T, Clough D, Wright PM, et al: The influence
of mild hypothermia on the pharmacokinetics and time course of action of neostigmine
in anesthetized volunteers. Anesthesiology 97:90–95, 2002.
495.
Giesecke AH Jr, Morris RE, Dalton MD, et al:
Of magnesium, muscle relaxants, toxemic parturients, and cats. Anesth Analg 47:689–695,
1968.
496.
Sinatra RS, Philip BK, Naulty JS, et al: Prolonged
neuromuscular blockade with vecuronium in a patient treated with magnesium sulfate.
Anesth Analg 64:1220–1222, 1985.
497.
Fuchs-Buder T, Wilder-Smith OH, Borgeat A, et
al: Interaction of magnesium sulphate with vecuronium-induced neuromuscular block.
Br J Anaesth 74:405–409, 1995.
498.
Gaiser RR, Seem EH: Use of rocuronium in a pregnant
patient with an open eye injury, receiving magnesium medication, for preterm labour.
Br J Anaesth 77:669–671, 1996.
499.
Ahn EK, Bai SJ, Cho BJ, et al: The infusion rate
of mivacurium and its spontaneous neuromuscular recovery in magnesium-treated parturients.
Anesth Analg 86:523–526, 1998.
500.
Sloan PA, Rasul M: Prolongation of rapacuronium
neuromuscular blockade by clindamycin and magnesium. Anesth Analg 94:123–124,
2002.
501.
Fuchs-Buder T, Ziegenfuss T, Lysakowski K, et
al: Antagonism of vecuronium-induced neuromuscular block in patients pretreated
with magnesium sulphate: Dose-effect relationship of neostigmine. Br J Anaesth
82:61–65, 1999.
502.
McLarnon JG, Quastel DM: Postsynaptic effects
of magnesium and calcium at the mouse neuromuscular junction. J Neurosci 3:1626–1633,
1983.
503.
Ghoneim MM, Long JP: The interaction between
magnesium and other neuromuscular blocking agents. Anesthesiology 32:23–27,
1970.
504.
James MF, Cork RC, Dennett JE: Succinylcholine
pretreatment with magnesium sulfate. Anesth Analg 65:373–376, 1986.
505.
Tsai SK, Huang SW, Lee TY: Neuromuscular interactions
between suxamethonium and magnesium sulphate in the cat. Br J Anaesth 72:674–678,
1994.
506.
Waud BE, Waud DR: Interaction of calcium and
potassium with neuromuscular blocking agents. Br J Anaesth 52:863–866, 1980.
507.
Al-Mohaya S, Naguib M, Abdelatif M, et al: Abnormal
responses to muscle relaxants in a patient with primary hyperparathyroidism. Anesthesiology
65:554–556, 1986.
508.
Ward ME, Musa MN, Bailey L: Clinical pharmacokinetics
of lithium. J Clin Pharmacol 34:280–285, 1994.
509.
Price LH, Heninger GR: Lithium in the treatment
of mood disorders. N Engl J Med 331:591–598, 1994.
510.
Abdel-Zaher AO: The myoneural effects of lithium
chloride on the nerve-muscle preparations of rats. Role of adenosine triphosphate-sensitive
potassium channels. Pharmacol Res 41:163–178, 2000.
511.
Naguib M, Koorn R: Interactions between psychotropics,
anaesthetics and electroconvulsive therapy: Implications for drug choice and patient
management. CNS Drugs 16:229–247, 2002.
512.
Hill GE, Wong KC, Hodges MR: Potentiation of
succinylcholine neuromuscular blockade by lithium carbonate. Anesthesiology 44:439–442,
1976.
513.
Hill GE, Wong KC, Hodges MR: Lithium carbonate
and neuromuscular blocking agents. Anesthesiology 46:122–126, 1977.
514.
Reimherr FW, Hodges MR, Hill GE, et al: Prolongation
of muscle relaxant effects by lithium carbonate. Am J Psychiatry 134:205–206,
1977.
515.
Havdala HS, Borison RL, Diamond BI: Potential
hazards and applications of lithium in anesthesiology. Anesthesiology 50:534–537,
1979.
516.
Borden H, Clarke MT, Katz H: The use of pancuronium
bromide in patients receiving lithium carbonate. Can Anaesth Soc J 21:79–82,
1974.
517.
Martin BA, Kramer PM: Clinical significance of
the interaction between lithium and a neuromuscular blocker. Am J Psychiatry 139:1326–1328,
1982.
518.
Telivuo L, Katz RL: The effects of modern intravenous
local analgesics on respiration during partial neuromuscular block in man. Anaesthesia
25:30–35, 1970.
519.
Usubiaga JE, Wikinski JA, Morales RL, et al:
Interaction of intravenously administered procaine, lidocaine and succinylcholine
in anesthetized subjects. Anesth Analg 46:39–45, 1967.
520.
Usubiaga JE, Standaert F: The effects of local
anesthetics on motor nerve terminals. J Pharmacol Exp Ther 159:353–361, 1968.
521.
Kordas M: The effect of procaine on neuromuscular
transmission. J Physiol 209:689–699, 1970.
522.
Thorpe WR, Seeman P: The site of action of caffeine
and procaine in skeletal muscle. J Pharmacol Exp Ther 179:324–330, 1971.
523.
Harrah MD, Way WL, Katzung BG: The interaction
of d-tubocurarine with antiarrhythmic drugs. Anesthesiology
33:406–410, 1970.
524.
Miller RD, Way WL, Katzung BG: The potentiation
of neuromuscular blocking agents by quinidine. Anesthesiology 28:1036–1041,
1967.
525.
Salvador A, del Pozo E, Carlos R, et al: Differential
effects of calcium channel blocking agents on pancuronium- and suxamethonium-induced
neuromuscular blockade. Br J Anaesth 60:495–499, 1988.
526.
Bell PF, Mirakhur RK, Elliott P: Onset and duration
of clinical relaxation of atracurium and vecuronium in patients on chronic nifedipine
therapy. Eur J Anaesthesiol 6:343–346, 1989.
527.
Kanaya N, Sato Y, Tsuchida H, et al: The effects
of nicardipine and verapamil on the recovery time of vecuronium-induced neuromuscular
blockade [in Japanese]. Masui 40:246–249, 1991.
528.
van Poorten JF, Dhasmana KM, Kuypers RS, et al:
Verapamil and reversal of vecuronium neuromuscular blockade. Anesth Analg 63:155–157,
1984.
529.
Baurain M, Barvais L, d'Hollander A, et al: Impairment
of the antagonism of vecuronium-induced paralysis and intra-operative disopyramide
administration. Anaesthesia 44:34–36, 1989.
530.
Selzer ME, David G, Yaari Y: Phenytoin reduces
frequency potentiation of synaptic potentials at the frog neuromuscular junction.
Brain Res 304:149–152, 1984.
531.
Selzer ME, David G, Yaari Y: On the mechanism
by which phenytoin blocks post-tetanic potentiation at the frog neuromuscular junction.
J Neurosci 5:2894–2899, 1985.
532.
Jellish WS, Modica PA, Tempelhoff R: Accelerated
recovery from pipecuronium in patients treated with chronic anticonvulsant therapy.
J Clin Anesth 5:105–108, 1993.
533.
Ornstein E, Matteo RS, Schwartz AE, et al: The
effect of phenytoin on the magnitude and duration of neuromuscular block following
atracurium or vecuronium. Anesthesiology 67:191–196, 1987.
534.
Spacek A, Neiger FX, Spiss CK, et al: Chronic
carbamazepine therapy does not influence mivacurium-induced neuromuscular block.
Br J Anaesth 77:500–502, 1996.
535.
Spacek A, Neiger FX, Spiss CK, et al: Atracurium-induced
neuromuscular block is not affected by chronic anticonvulsant therapy with carbamazepine.
Acta Anaesthesiol Scand 41:1308–1311, 1997.
536.
Roth S, Ebrahim ZY: Resistance to pancuronium
in patients receiving carbamazepine. Anesthesiology 66:691–693, 1987.
537.
Ornstein E, Matteo RS, Weinstein JA, et al: Accelerated
recovery from doxacurium-induced neuromuscular blockade in patients receiving chronic
anticonvulsant therapy. J Clin Anesth 3:108–111, 1991.
538.
Whalley DG, Ebrahim Z: Influence of carbamazepine
on the dose-response relationship of vecuronium. Br J Anaesth 72:125–126,
1994.
539.
Alloul K, Whalley DG, Shutway F, et al: Pharmacokinetic
origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in
anesthetized patients. Anesthesiology 84:330–339, 1996.
540.
Kim CS, Arnold FJ, Itani MS, et al: Decreased
sensitivity to metocurine during long-term phenytoin therapy may be attributable
to protein binding and acetylcholine receptor changes. Anesthesiology 77:500–506,
1992.
541.
Melton AT, Antognini JF, Gronert GA: Prolonged
duration of succinylcholine in patients receiving anticonvulsants: Evidence for
mild up-regulation of acetylcholine receptors? Can J Anaesth 40:939–942, 1993.
542.
Miller RD, Sohn YJ, Matteo RS: Enhancement of
d-tubocurarine neuromuscular blockade by diuretics
in man. Anesthesiology 45:442–445, 1976.
543.
Scappaticci KA, Ham JA, Sohn YJ, et al: Effects
of furosemide on the neuromuscular junction. Anesthesiology 57:381–388, 1982.
544.
Carmignani M, Scoppetta C, Ranelletti FO, et al:
Adverse interaction between acetazolamide and anticholinesterase drugs at the normal
and myasthenic neuromuscular junction level. Int J Clin Pharmacol Ther Toxicol 22:140–144,
1984.
545.
Azar I, Cottrell J, Gupta B, et al: Furosemide
facilitates recovery of evoked twitch response after pancuronium. Anesth Analg 59:55–57,
1980.
546.
Hill GE, Wong KC, Shaw CL, et al: Acute and chronic
changes in intra- and extracellular potassium and responses to neuromuscular blocking
agents. Anesth Analg 57:417–421, 1978.
547.
Nott MW, Bowman WC: Actions of dantrolene sodium
on contractions of the tibialis anterior and soleus muscles of cats under chloralose
anaesthesia. Clin Exp Pharmacol Physiol 1:113–122, 1974.
548.
Morgan KG, Bryant SH: The mechanism of action
of dantrolene sodium. J Pharmacol Exp Ther 201:138–147, 1977.
549.
Gramstad L: Atracurium, vecuronium and pancuronium
in end-stage renal failure. Dose-response properties and interactions with azathioprine.
Br J Anaesth 59:995–1003, 1987.
550.
Glidden RS, Martyn JA, Tomera JF: Azathioprine
fails to alter the dose-response curve of d-tubocurarine
in rats. Anesthesiology 68:595–598, 1988.
551.
Meyers EF: Partial recovery from pancuronium
neuromuscular blockade following hydrocortisone administration. Anesthesiology 46:148–150,
1977.
552.
Reddy P, Guzman A, Robalino J, et al: Resistance
to muscle relaxants in a patient receiving prolonged testosterone therapy. Anesthesiology
70:871–873, 1989.
553.
Arts WF, Oosterhuis HJ: Effect of prednisolone
on neuromuscular blocking in mice in vivo. Neurology 25:1088–1090, 1975.
554.
Leeuwin RS, Veldsema-Currie RD, van Wilgenburg
H, et al: Effects of corticosteroids on neuromuscular blocking actions of d-tubocurarine.
Eur J Pharmacol 69:165–173, 1981.
555.
Hall ED: Glucocorticoid modification of the responsiveness
of a fast (type 2) neuromuscular system to edrophonium and d-tubocurarine.
Exp Neurol 69:349–358, 1980.
556.
Parr SM, Robinson BJ, Rees D, et al: Interaction
between betamethasone and vecuronium. Br J Anaesth 67:447–451, 1991.
557.
Bouzat C, Barrantes FJ: Modulation of muscle
nicotinic acetylcholine receptors by the glucocorticoid hydrocortisone. Possible
allosteric mechanism of channel blockade. J Biol Chem 271:25835–25841, 1996.
558.
Valera S, Ballivet M, Bertrand D: Progesterone
modulates a neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A
89:9949–9953, 1992.
559.
Naguib M, Gyasi HK: Antiestrogenic drugs and
atracurium—a possible interaction? Can Anaesth Soc J 33:682–683, 1986.
560.
Ali HH, Utting JE, Gray TC: Quantitative assessment
of residual antidepolarizing block. II. Br J Anaesth 43:478–485, 1971.
561.
Ali HH, Kitz RJ: Evaluation of recovery from
nondepolarizing neuromuscular block, using a digital neuromuscular transmission analyzer:
Preliminary report. Anesth Analg 52:740–745, 1973.
562.
Howardy-Hansen P, Moller J, Hansen B: Pretreatment
with atracurium: The influence on neuromuscular transmission and pulmonary function.
Acta Anaesthesiol Scand 31:642–644, 1987.
563.
Eriksson LI, Sundman E, Olsson R, et al: Functional
assessment of the pharynx at rest and during swallowing in partially paralyzed humans:
Simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology
87:1035–1043, 1997.
564.
Sundman E, Witt H, Olsson R, et al: The incidence
and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed
humans: Pharyngeal videoradiography and simultaneous manometry after atracurium.
Anesthesiology 92:977–984, 2000.
565.
Eriksson LI: Reduced hypoxic chemosensitivity
in partially paralysed man. A new property of muscle relaxants? Acta Anaesthesiol
Scand 40:520–523, 1996.
566.
Eriksson LI: The effects of residual neuromuscular
blockade and volatile anesthetics on the control of ventilation. Anesth Analg 89:243–251,
1999.
567.
Igarashi A, Amagasa S, Horikawa H, et al: Vecuronium
directly inhibits hypoxic neurotransmission of the rat carotid body. Anesth Analg
94:117–122, 2002.
568.
Viby-Mogensen J: Postoperative residual curarization
and evidence-based anaesthesia. Br J Anaesth 84:301–303, 2000.
569.
Lien CA, Matteo RS, Ornstein E, et al: Distribution,
elimination, and action of vecuronium in the elderly. Anesth Analg 73:39–42,
1991.
570.
Caldwell JE: Reversal of residual neuromuscular
block with neostigmine at one to four hours after a single intubating dose of vecuronium.
Anesth Analg 80:1168–1174, 1995.
571.
Magorian TT, Lynam DP, Caldwell JE, et al: Can
early administration of neostigmine, in single or repeated doses, alter the course
of neuromuscular recovery from a vecuronium-induced neuromuscular blockade? Anesthesiology
73:410–414, 1990.
572.
Baurain MJ, d'Hollander AA, Melot C, et al: Effects
of residual concentrations of isoflurane on the reversal of vecuronium-induced neuromuscular
blockade. Anesthesiology 74:474–478, 1991.
573.
McMahan UJ, Sanes JR, Marshall LM: Cholinesterase
is associated with the basal lamina at the neuromuscular junction. Nature 271:172–174,
1978.
574.
Zhou HX, Wlodek ST, McCammon JA: Conformation
gating as a mechanism for enzyme specificity. Proc Natl Acad Sci U S A 95:9280–9283,
1998.
575.
Soreq H, Seidman S: Acetylcholinesterase—new
roles for an old actor. Nat Rev Neurosci 2:294–302, 2001.
576.
Wilson IB, Bergmann F: Studies on cholinesterase.
VII. The active surface of acetylcholine esterase derived from effects of pH on
inhibitors. J Biol Chem 185:479–489, 1950.
577.
Bergmann F, Wilson IB, Nachmansohn D: The inhibitory
effect of stilbamidine, curare and related compounds and its relationship to the
active groups of acetylcholine esterase. Biochim Biophys Acta 6:217–224, 1950.
578.
Wilson IB: The interaction of Tensilon and neostigmine
with acetylcholinesterase. Arch Int Pharmacodyn 54:204–213, 1955.
579.
Bevan DR, Donati F, Kopman AF: Reversal of neuromuscular
blockade. Anesthesiology 77:785–805, 1992.
580.
Mirakhur RK: Basic pharmacology of reversal agents.
Anesthesiol Clin North Am 11:237, 1993.
581.
Beattie WS, Buckley DN, Forrest JB: Continuous
infusions of atracurium and vecuronium, compared with intermittent boluses of pancuronium:
Dose requirements and reversal. Can J Anaesth 39:925–931, 1992.
582.
Beemer GH, Goonetilleke PH, Bjorksten AR: The
maximum depth of an atracurium neuromuscular block antagonized by edrophonium to
effect adequate recovery. Anesthesiology 82:852–858, 1995.
583.
Bevan JC, Collins L, Fowler C, et al: Early and
late reversal of rocuronium and vecuronium with neostigmine in adults and children.
Anesth Analg 89:333–339, 1999.
584.
Kirkegaard H, Heier T, Caldwell JE: Efficacy
of tactile-guided reversal from cisatracurium-induced neuromuscular block. Anesthesiology
96:45–50, 2002.
585.
Cronnelly R, Morris RB, Miller RD: Edrophonium:
Duration of action and atropine requirement in humans during halothane anesthesia.
Anesthesiology 57:261–266, 1982.
586.
Beemer GH, Bjorksten AR, Dawson PJ, et al: Determinants
of the reversal time of competitive neuromuscular block by anticholinesterases.
Br J Anaesth 66:469–475, 1991.
587.
Caldwell JE, Robertson EN, Baird WL: Antagonism
of vecuronium and atracurium: Comparison of neostigmine and edrophonium administered
at 5% twitch height recovery. Br J Anaesth 59:478–481, 1987.
588.
Miller RD, Van Nyhuis LS, Eger EI 2nd, et al:
Comparative times to peak effect and durations of action of neostigmine and pyridostigmine.
Anesthesiology 41:27–33, 1974.
589.
Rupp SM, McChristian JW, Miller RD, et al: Neostigmine
and edrophonium antagonism of varying intensity neuromuscular blockade induced by
atracurium, pancuronium, or vecuronium. Anesthesiology 64:711–717, 1986.
590.
Engbaek J, Ording H, Ostergaard D, et al: Edrophonium
and neostigmine for reversal of the neuromuscular blocking effect of vecuronium.
Acta Anaesthesiol Scand 29:544–546, 1985.
591.
Donati F, Smith CE, Bevan DR: Dose-response relationships
for edrophonium and neostigmine as antagonists of moderate and profound atracurium
blockade. Anesth Analg 68:13–19, 1989.
592.
Cronnelly R: Muscle relaxant antagonists. Semin
Anesth 4:31, 1985.
593.
Donati F, McCarroll SM, Antzaka C, et al: Dose-response
curves for edrophonium, neostigmine, and pyridostigmine after pancuronium and d-tubocurarine.
Anesthesiology 66:471–476, 1987.
594.
Naguib M, Abdulatif M: Priming with anti-cholinesterases—the
effect of different priming doses of edrophonium. Can J Anaesth 35:53–57,
1988.
595.
Naguib M, Abdulatif M: Priming with anti-cholinesterases—the
effect of different combinations of anti-cholinesterases and different priming intervals.
Can J Anaesth 35:47–52, 1988.
596.
Savarese JJ: Reversal of nondepolarizing blocks:
More controversial than ever? Review Course Lectures, 67th Congress, Cleveland,
Ohio, International Anesthesia Research Society, 1993.
597.
Eriksson LL: Evidence-based practice and neuromuscular
monitoring: It's time for routine quantitative assessment. Anesthesiology 98:1037–1039,
2003.
598.
Deboene B, Plaud B, Dilly MP, Donati F: Residual
paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant
with an intermediate duration of action. Anesthesiology 98:1042–1048, 2003.
599.
Naguib M, Abdulatif M, al-Ghamdi A, et al: Dose-response
relationships for edrophonium and neostigmine antagonism of mivacurium-induced neuromuscular
block. Br J Anaesth 71:709–714, 1993.
600.
Kao YJ, Le ND: The reversal of profound mivacurium-induced
neuromuscular blockade. Can J Anaesth 43:1128–1133, 1996.
